Amicus abandons wound treatment, focus shifts to future trial data

(Reuters) - Amicus Therapeutics Inc said on Wednesday it would stop developing its experimental drug for healing wounds related to a rare skin disease, but shares of the company rose as investors appeared to focus on the drug developer's expanding pipeline.